Menarini
Menarini Group, a prominent player in the pharmaceutical industry, is headquartered in Florence, Italy. Founded in 1886, the company has established a strong presence across Europe, Asia, and the Americas, focusing on research, development, and the manufacturing of innovative healthcare solutions. Specialising in prescription pharmaceuticals, over-the-counter products, and diagnostics, Menarini is recognised for its commitment to quality and patient care. The company’s core offerings include therapeutic areas such as oncology, cardiology, and infectious diseases, distinguished by their efficacy and safety profiles. With a rich history of milestones, Menarini has achieved significant market position, consistently ranking among the top pharmaceutical companies in Italy. Its dedication to advancing medical science and improving patient outcomes underscores its reputation as a trusted name in healthcare.
DitchCarbon Score
How does Menarini's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Menarini's score of 13 is lower than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Menarini's reported carbon emissions
In 2023, Menarini reported total carbon emissions of approximately 1,139,380 kg CO2e, comprising 100,390 kg CO2e from Scope 1, 26,250 kg CO2e from Scope 2, and 1,125,130 kg CO2e from Scope 3 emissions. This represents a slight decrease in total emissions compared to 2022, where the company recorded about 1,299,240 kg CO2e, with 47,200 kg CO2e from Scope 1, 21,970 kg CO2e from Scope 2, and 1,275,970 kg CO2e from Scope 3. Menarini has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. However, the company is actively monitoring its emissions across all scopes, indicating a commitment to improving its environmental performance. As a leading pharmaceutical company headquartered in Italy, Menarini is positioned to contribute to industry-wide efforts in reducing carbon footprints and addressing climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Menarini is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
